CPIC指南2026更新:CYP2D6基因型与5-HT3受体拮抗剂的使用
该指南是2016年CPIC指南的更新,针对CYP2D6基因型与5-HT3受体拮抗剂(昂丹司琼、托烷司琼等)的使用提供治疗推荐。指南总结了CYP2D6遗传变异影响这些药物代谢(尤其是昂丹司琼和托烷司琼)从而影响疗效的证据,并更新了CYP2D6基因检测信息和证据表。
要点
- CYP2D6基因变异可影响昂丹司琼和托烷司琼代谢,进而影响疗效。
- 指南基于CYP2D6基因型提供5-HT3受体拮抗剂治疗推荐。
- 更新了CYP2D6基因检测信息和证据表。
核心结论
- CYP2D6遗传变异与5-HT3受体拮抗剂(尤其是昂丹司琼和托烷司琼)疗效降低相关,指南据此提供治疗推荐。
研究设计与样本
- CPIC指南更新,基于已发表文献证据总结,并提供基于CYP2D6基因型的治疗推荐。
主要发现
- 大多数5-HT3受体拮抗剂(昂丹司琼、托烷司琼、多拉司琼、帕洛诺司琼和雷莫司琼)由CYP2D6代谢,但CYP2D6参与程度不同。
- CYP2D6遗传变异可影响这些药物的代谢,尤其是昂丹司琼和托烷司琼,从而影响药物疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy-induced, radiation-induced, and postoperative nausea and vomiting. Most of the 5-HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent of CYP2D6 involvement varies. CYP2D6 genetic variation can influence the metabolism of these medications, particularly ondansetron and tropisetron, thereby affecting drug efficacy. This guideline is an update to the 2016 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron and includes updated information on CYP2D6 genetic testing and evidence tables. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for 5-HT3 receptor antagonists based on CYP2D6 genotype, particularly where genetic variation is associated with reduced drug efficacy (updates at https://www.clinpgx.org/guideline/PA166251457).
引用
- Moore C, Bourque MS, Halman A, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT3 Receptor Antagonists: 2026 Update. Clin Pharmacol Ther. 2026. PMID: 41979467. doi:10.1002/cpt.70291
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。